Shattuck Labs, Inc. cash flow statement
In fiscal 2025, Shattuck Labs, Inc.'s operations generated −$39.9m of cash; it spent $71,000 on capital projects, leaving free cash flow of −$40.0m.
Cash flow statement
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −21 | −34 | −57 | −94 | −81 | −61 | −40 | −41 |
| Depreciation and amortisation | 1 | 1 | 1 | 3 | 4 | 4 | 4 | 4 |
| Stock-based pay | 0 | 1 | 5 | 6 | 7 | 10 | 7 | 9 |
| Capital spending | 0 | 1 | 8 | 12 | 0 | 0 | 0 | 0 |
| Free cash flow | −21 | −34 | −65 | −106 | −82 | −61 | −40 | −41 |
| Free cash flow after stock pay | −22 | −36 | −71 | −113 | −89 | −70 | −47 | −50 |
| Shares issued | — | — | — | 0 | 48 | — | 44 | 145 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −16 | −17 | −12 | −10 | −9 | −8 | −13 | −10 |
| Depreciation and amortisation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Stock-based pay | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 3 |
| Capital spending | 0 | 0 | — | — | 0 | 0 | — | 0 |
| Free cash flow | −16 | −17 | — | — | −9 | −8 | — | −10 |
| Free cash flow after stock pay | −19 | −19 | — | — | −11 | −10 | — | −13 |
| Shares issued | 0 | — | 0 | 0 | 44 | −0 | 21 | 80 |
Compare with peers
- Medicinova Inc cash flow
- Longeveron Inc. cash flow
- Dare Bioscience, Inc. cash flow
- Cartesian Therapeutics, Inc. cash flow
- Absci Corp cash flow
Head to head: MNOV vs STTKLGVN vs STTKDARE vs STTK
More: Biotechnology stocks compared, Health Care sector, rankings of US companies